9 / 31
Heinemann V, et al. Ann Oncol 2015.
RR is the relative risk, EGFRI + CTx/bevacizumab + CTx (%).
Weight is relative weight (%) from the fixed effect model.
Heterogeneity: Chi
2
= 2.81, df = 2, (P = 0.25), I
2
= 29%, Tau
2
= 0
(n = 526)
(n = 342)
(n = 169)
0.78
(0.68−0.90)
0.91
(0.77−1.07)
0.95
(0.75−1.21)
0.85
(0.77−0.94)
0.86
(0.76−0.97)
−0.243
−0.094
−0.050
0.0839
0.1206
48.5
34.7
16.8
100
0.0710
CALGB
FIRE-3
PEAK
Total
Total
(fixed)
(random)
RR (95% CI)
logRR
logSE
Weight
0.1
1
10
WT
RAS
Favours anti-EGFR + CTx
Favours bevacizumab + CTx
Response Rate